



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANT: Ben-Sasson et al.  
SERIAL NUMBER: 10/664,989 EXAMINER: Susan T. Tran  
FILING DATE: September 17, 2003 ART UNIT: 1615  
FOR: COMPOSITIONS CAPABLE OF FACILITATING PENETRATION  
ACROSS A BIOLOGICAL MEMBRANE

MAIL STOP AMENDMENT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TRANSMITTAL LETTER**

Sir:

Transmitted herewith for filing in the present application are the following documents:

- ☒ Response to Restriction Requirement (2 pgs.); and
- ☒ Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room is respectfully requested to contact the undersigned collect at (617) 542-6000, Boston, Massachusetts. The Commissioner is authorized to credit any overpayment or charge any deficiencies to Deposit Account No. 50-0311, Reference No. 24348-502. A duplicate copy of this Transmittal Letter is enclosed.

Respectfully submitted,

Ivor R. Elrifi, Reg. No. 39,529  
Christina K. Stock, Reg. No. 45,899  
Attorneys for Applicant  
Tel.: (617) 542 6000  
Fax: (617) 542-2241  
Customer No. 30623

Date: November 29, 2006

Express Mail Label No.: EV978766973US

Date of Deposit: November 29, 2006

Attorney Docket No. 24348-502



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**APPLICANT(S):** Ben-Sasson *et al.*

**APPLICATION NO:** 10/664,989

**EXAMINER:** Susan T. Tran

**FILING DATE:** September 17, 2003

**ART UNIT:** 1615

**FOR:** COMPOSITIONS CAPABLE OF FACILITATING PENETRATION ACROSS A BIOLOGICAL MEMBRANE

Mail Stop AMENDMENT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

November 29, 2006  
Boston, Massachusetts

**RESPONSE TO RESTRICTON REQUIREMENT**

This paper is in response to the Restriction Requirement mailed on October 31, 2006 in the above-referenced application. Applicants elect the invention of Group II, claims 17 and 18, drawn to a composition comprising at least one effector that is a pharmaceutically active agent, classified in class 424, subclass 451-464, without traverse. With regard to the species elections, Applicants elect the capsule composition; a bioactive molecule for the anionic impermeable molecule; imidazolium derivatives for the ionic liquid forming cation; tri-glycerides as the hydrophobic carrier; and the gastrointestinal mucosa for the biological barrier. As noted by the Examiner, claim 1 is generic. (*See* Restriction Requirement at page 6). Moreover, claims 2, 4, 11, 15-16, 22-25, 29-31, 42 and 45 read on the elected species.

Applicants understand that, upon allowance of the linking claim, the Restriction Requirement as to the linked inventions shall be withdrawn and any claims depending therefrom or otherwise requiring all of the limitations of the allowed linking claims will be rejoined and fully examined for patentability in accordance with 37 C.F.R. § 1.104. (*See* Restriction Requirement at page 3). Applicants note that the election of species is made for the purpose of examination of the claims only and that Applicants maintain the right to have the full scope of the claims, as written, examined on the merits. Further, Applicants reserve the right to prosecute the non-elected claims and species in one or more continuation or divisional applications.

With no extension, this response is due on or before November 30, 2006. Thus, Applicants believe no fees are due in connection with this filing. However, the Commissioner is authorized to charge any additional fees that may be due, or to credit any overpayment, to Deposit Account No. 50-0311, Ref. No. 24348-502.

Respectfully submitted,



Dated: November 29, 2006

~~Ivor R. Elrifi~~, Reg. No. 89,529  
Christina K. Stock, Reg. No. 45, 899  
Attorneys for Applicants  
c/o MINTZ, LEVIN  
One Financial Center  
Boston, Massachusetts 02111  
Tel: (617) 542-6000  
Fax: (617) 542-2241